Tweet
Open Forum Infect Dis
. 2023 May 23;10(7):ofad275.
doi: 10.1093/ofid/ofad275. eCollection 2023 Jul. Association Between SARS-CoV-2 Variants and Frequency of Acute Symptoms: Analysis of a Multi-institutional Prospective Cohort Study-December 20, 2020-June 20, 2022
Ralph C Wang 1 , Michael Gottlieb 2 , Juan Carlos C Montoy 1 , Robert M Rodriguez 1 , Huihui Yu 3 , Erica S Spatz 3 , Christopher W Chandler 4 , Joann G Elmore 4 5 , Paavali A Hannikainen 6 , Anna Marie Chang 6 , Mandy Hill 7 , Ryan M Huebinger 7 , Ahamed H Idris 8 , Katherine Koo 9 , Shu-Xia Li 3 , Samuel McDonald 8 , Graham Nichol 10 , Kelli N O'Laughlin 11 , Ian D Plumb 12 , Michelle Santangelo 13 , Sharon Saydah 12 , Kari A Stephens 14 , Arjun K Venkatesh 3 15 , Robert A Weinstein 9 ; Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE) Group
Collaborators, Affiliations
Background: While prior work examining severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern focused on hospitalization and death, less is known about differences in clinical presentation. We compared the prevalence of acute symptoms across pre-Delta, Delta, and Omicron.
Methods: We conducted an analysis of the Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE), a cohort study enrolling symptomatic SARS-CoV-2-positive participants. We determined the association between the pre-Delta, Delta, and Omicron time periods and the prevalence of 21 coronavirus disease 2019 (COVID-19) acute symptoms.
Results: We enrolled 4113 participants from December 2020 to June 2022. Pre-Delta vs Delta vs Omicron participants had increasing sore throat (40.9%, 54.6%, 70.6%; P < .001), cough (50.9%, 63.3%, 66.7%; P < .001), and runny noses (48.9%, 71.3%, 72.9%; P < .001). We observed reductions during Omicron in chest pain (31.1%, 24.2%, 20.9%; P < .001), shortness of breath (42.7%, 29.5%, 27.5%; P < .001), loss of taste (47.1%, 61.8%, 19.2%; P < .001), and loss of smell (47.5%, 55.6%, 20.0%; P < .001). After adjustment, those infected during Omicron had significantly higher odds of sore throat vs pre-Delta (odds ratio [OR], 2.76; 95% CI, 2.26-3.35) and Delta (OR, 1.96; 95% CI, 1.69-2.28).
Conclusions: Participants infected during Omicron were more likely to report symptoms of common respiratory viruses, such as sore throat, and less likely to report loss of smell and taste.
Trial registration: NCT04610515.
Keywords: COVID-19; COVID-19 symptoms; SARS-COV-2; variants of concern.
. 2023 May 23;10(7):ofad275.
doi: 10.1093/ofid/ofad275. eCollection 2023 Jul. Association Between SARS-CoV-2 Variants and Frequency of Acute Symptoms: Analysis of a Multi-institutional Prospective Cohort Study-December 20, 2020-June 20, 2022
Ralph C Wang 1 , Michael Gottlieb 2 , Juan Carlos C Montoy 1 , Robert M Rodriguez 1 , Huihui Yu 3 , Erica S Spatz 3 , Christopher W Chandler 4 , Joann G Elmore 4 5 , Paavali A Hannikainen 6 , Anna Marie Chang 6 , Mandy Hill 7 , Ryan M Huebinger 7 , Ahamed H Idris 8 , Katherine Koo 9 , Shu-Xia Li 3 , Samuel McDonald 8 , Graham Nichol 10 , Kelli N O'Laughlin 11 , Ian D Plumb 12 , Michelle Santangelo 13 , Sharon Saydah 12 , Kari A Stephens 14 , Arjun K Venkatesh 3 15 , Robert A Weinstein 9 ; Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE) Group
Collaborators, Affiliations
- PMID: 37426947
- PMCID: PMC10327880
- DOI: 10.1093/ofid/ofad275
Background: While prior work examining severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern focused on hospitalization and death, less is known about differences in clinical presentation. We compared the prevalence of acute symptoms across pre-Delta, Delta, and Omicron.
Methods: We conducted an analysis of the Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE), a cohort study enrolling symptomatic SARS-CoV-2-positive participants. We determined the association between the pre-Delta, Delta, and Omicron time periods and the prevalence of 21 coronavirus disease 2019 (COVID-19) acute symptoms.
Results: We enrolled 4113 participants from December 2020 to June 2022. Pre-Delta vs Delta vs Omicron participants had increasing sore throat (40.9%, 54.6%, 70.6%; P < .001), cough (50.9%, 63.3%, 66.7%; P < .001), and runny noses (48.9%, 71.3%, 72.9%; P < .001). We observed reductions during Omicron in chest pain (31.1%, 24.2%, 20.9%; P < .001), shortness of breath (42.7%, 29.5%, 27.5%; P < .001), loss of taste (47.1%, 61.8%, 19.2%; P < .001), and loss of smell (47.5%, 55.6%, 20.0%; P < .001). After adjustment, those infected during Omicron had significantly higher odds of sore throat vs pre-Delta (odds ratio [OR], 2.76; 95% CI, 2.26-3.35) and Delta (OR, 1.96; 95% CI, 1.69-2.28).
Conclusions: Participants infected during Omicron were more likely to report symptoms of common respiratory viruses, such as sore throat, and less likely to report loss of smell and taste.
Trial registration: NCT04610515.
Keywords: COVID-19; COVID-19 symptoms; SARS-COV-2; variants of concern.